WO2003013655A3 - Carbonic anhydrase inhibitors - Google Patents
Carbonic anhydrase inhibitors Download PDFInfo
- Publication number
- WO2003013655A3 WO2003013655A3 PCT/US2002/025447 US0225447W WO03013655A3 WO 2003013655 A3 WO2003013655 A3 WO 2003013655A3 US 0225447 W US0225447 W US 0225447W WO 03013655 A3 WO03013655 A3 WO 03013655A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- carbonic anhydrase
- drugs
- inhibitors
- anhydrase inhibitors
- cyclooxygenase
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02768491A EP1414522A2 (en) | 2001-08-10 | 2002-08-09 | Carbonic anhydrase inhibitors |
AU2002331050A AU2002331050A1 (en) | 2001-08-10 | 2002-08-09 | Carbonic anhydrase inhibitors |
CA002456939A CA2456939A1 (en) | 2001-08-10 | 2002-08-09 | Carbonic anhydrase inhibitors |
JP2003518654A JP2005501083A (en) | 2001-08-10 | 2002-08-09 | Carbonic anhydrase inhibitor |
BR0211836-0A BR0211836A (en) | 2001-08-10 | 2002-08-09 | Carbonic anhydrase inhibitor |
MXPA04001268A MXPA04001268A (en) | 2001-08-10 | 2002-08-09 | Carbonic anhydrase inhibitor. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31156101P | 2001-08-10 | 2001-08-10 | |
US60/311,561 | 2001-08-10 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003013655A2 WO2003013655A2 (en) | 2003-02-20 |
WO2003013655A3 true WO2003013655A3 (en) | 2003-08-14 |
Family
ID=23207450
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/025447 WO2003013655A2 (en) | 2001-08-10 | 2002-08-09 | Carbonic anhydrase inhibitors |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1414522A2 (en) |
JP (1) | JP2005501083A (en) |
AU (1) | AU2002331050A1 (en) |
BR (1) | BR0211836A (en) |
CA (1) | CA2456939A1 (en) |
MX (1) | MXPA04001268A (en) |
WO (1) | WO2003013655A2 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030100594A1 (en) * | 2001-08-10 | 2003-05-29 | Pharmacia Corporation | Carbonic anhydrase inhibitor |
OA13170A (en) * | 2003-05-22 | 2006-12-13 | Pharmacia Italia Spa | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors. |
LT5504B (en) * | 2006-08-02 | 2008-06-25 | Biotechnologijos Institutas | Benzimidazo[1,2-c][1,2,3]thiadiazol-7-sulfonamides as inhibitors of carbonic anhydrase and the intermediates for production thereof |
CA2777071A1 (en) * | 2009-10-21 | 2011-04-28 | Bayer Pharma Aktiengesellschaft | Substituted halophenoxybenzamide derivatives |
BR112018000065B1 (en) * | 2015-07-01 | 2023-11-07 | Signalchem Lifesciences Corporation | ARYL SULFONAMIDE COMPOUNDS AS CARBONIC ANHYDRASE INHIBITORS, PHARMACEUTICAL COMPOSITION COMPRISING SAID COMPOUNDS AND THERAPEUTIC USES THEREOF IN THE TREATMENT OF CANCER |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997038986A1 (en) * | 1996-04-12 | 1997-10-23 | G.D. Searle & Co. | Substituted benzenesulfonamide derivatives as prodrugs of cox-2 inhibitors |
EP0826676A1 (en) * | 1994-12-20 | 1998-03-04 | Japan Tobacco Inc. | Oxazole derivatives and use thereof |
US5760068A (en) * | 1993-11-30 | 1998-06-02 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation |
US5944021A (en) * | 1995-06-07 | 1999-08-31 | Rodriguez; Victorio C. | Therapeutic use of a carbonic anhydrase enzyme inhibitor for the treatment of brain edema |
WO2001028548A1 (en) * | 1999-10-19 | 2001-04-26 | Texas Heart Institute | Treatment of heart disease with cox-2 inhibitors |
-
2002
- 2002-08-09 EP EP02768491A patent/EP1414522A2/en not_active Withdrawn
- 2002-08-09 CA CA002456939A patent/CA2456939A1/en not_active Abandoned
- 2002-08-09 JP JP2003518654A patent/JP2005501083A/en not_active Withdrawn
- 2002-08-09 MX MXPA04001268A patent/MXPA04001268A/en unknown
- 2002-08-09 WO PCT/US2002/025447 patent/WO2003013655A2/en not_active Application Discontinuation
- 2002-08-09 AU AU2002331050A patent/AU2002331050A1/en not_active Abandoned
- 2002-08-09 BR BR0211836-0A patent/BR0211836A/en not_active IP Right Cessation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5760068A (en) * | 1993-11-30 | 1998-06-02 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation |
EP0826676A1 (en) * | 1994-12-20 | 1998-03-04 | Japan Tobacco Inc. | Oxazole derivatives and use thereof |
US5944021A (en) * | 1995-06-07 | 1999-08-31 | Rodriguez; Victorio C. | Therapeutic use of a carbonic anhydrase enzyme inhibitor for the treatment of brain edema |
WO1997038986A1 (en) * | 1996-04-12 | 1997-10-23 | G.D. Searle & Co. | Substituted benzenesulfonamide derivatives as prodrugs of cox-2 inhibitors |
WO2001028548A1 (en) * | 1999-10-19 | 2001-04-26 | Texas Heart Institute | Treatment of heart disease with cox-2 inhibitors |
Non-Patent Citations (1)
Title |
---|
GRÜNEBERG, S. ET AL.,: "Subnanomolar Inhibitors from Computer Screening: A Model Study Using Human Carbonic Anhydrase II.", ANGEW. CHEM. INT. ED., vol. 40, no. 2, - 2001, pages 389 - 393, XP001126207 * |
Also Published As
Publication number | Publication date |
---|---|
JP2005501083A (en) | 2005-01-13 |
BR0211836A (en) | 2004-12-14 |
EP1414522A2 (en) | 2004-05-06 |
CA2456939A1 (en) | 2003-02-20 |
MXPA04001268A (en) | 2004-05-27 |
WO2003013655A2 (en) | 2003-02-20 |
AU2002331050A1 (en) | 2003-02-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004006858A3 (en) | Compounds, compositions, and methods employing same | |
WO2005009342A3 (en) | Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith | |
WO2004072031A3 (en) | Phenylacetamides and their use as glucokinase modulators | |
WO2002098444A3 (en) | Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis | |
WO2006033006A3 (en) | Therapeutic combinations comprising poly(adp-ribose) polymerases inhibitor | |
WO2006074265A3 (en) | Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders | |
WO2003090695A3 (en) | TREATMENT OF α-GALACTOSIDASE A DEFICIENCY | |
WO2005007142A3 (en) | Liquid compositions comprising formoterol | |
WO2002099388A3 (en) | Benzodiazepine bradykinin antagonists | |
WO2004096216A3 (en) | Use of a topical medicament comprising riluzole | |
WO2004105737A3 (en) | Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions using various agents | |
WO2004041245A3 (en) | Pharmaceutical solutions comprising a modafinil compound and their use for the manufacture of a medicament for treating different diseases | |
WO2008029237A3 (en) | Combination therapies for rheumatoid arthritis | |
WO2005009460A3 (en) | Pharmaceutical composition comprising activin a, alk-4 or derivatives thereof for the treatment of ophthalmic disorders or cancer | |
WO2004103283A3 (en) | Compositions of a cyclooxygenase-2 selective inhibitor and a central nervous system stimulant for the treatment of central nervous system damage | |
EP1440691A3 (en) | Treatment of neurotic disorders | |
AU2001256855A1 (en) | Preparation for the prevention and treatment of ocular disorders | |
WO2004073615A3 (en) | Deazaflavin compounds and methods of use thereof | |
WO2004041191A3 (en) | Methods for the treatment, prevention and management of macular degeneration | |
WO2003013655A3 (en) | Carbonic anhydrase inhibitors | |
WO2004034987A3 (en) | Treatment for reactive arthritis or bursitis | |
WO2003018535A3 (en) | Novel aminobenzoephenones | |
CA2414586A1 (en) | Agent for therapeutic treatment of optic nerve diseases and the like | |
WO2004047829A8 (en) | New synergistic combination comprising roflumilast and formoterol | |
WO2004087157A3 (en) | Combination of gh secretagogues and pde4 inhibitors for the treatment of alzheimer's disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2456939 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2004/001268 Country of ref document: MX Ref document number: 2002768491 Country of ref document: EP Ref document number: 2003518654 Country of ref document: JP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002768491 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2002768491 Country of ref document: EP |